Related Experiment Videos
Structural elucidation and structure-activity relationship of Porphyra haitanensis polysaccharide for preventing
Lu Sun1, Jiandong Li1, Qingyu Guan1
1School of Food Science and Engineering, Ocean University of China, Qingdao, 266003, People's Republic of China.
Abstract:
Polysaccharides from Porphyra haitanensis exhibited potential against ulcerative colitis (UC), whereas the mechanism remained unclear. In this study, Porphyra haitanensis polysaccharide (PP) was extracted by high-pressure-assisted hot water method. PP was characterized as a sulfated amorphous polysaccharide mainly consisting of galactose (85.65% ± 0.52 mol%) and fucose (11.24% ± 1.03 mol%), featuring a unique structure of →4)-α-L-Gal-6-S-(1 → 3)-β-D-Gal-(1 → 4)-3,6-anhydro-α-L-Gal-(1→ and a side chain of →6)-α-L-Fuc-(1→. Sulfation and amorphous morphology enabled PP with abundant active moieties and desirable biocompatibility for effective intestinal action. The high content β-galactose residues and fucose side chains endowed PP to exert superior immunomodulatory activity and promote the proliferation of Firmicutes, Lachnospiraceae_NK4A136_group and Ligilactobacillus. The gut microbiota compositional shifts triggered KEGG metabolic alterations, as enriched acid-producing bacteria reciprocally facilitated short-chain fatty acids (SCFAs) synthesis. By remodeling the intestinal microenvironment, SCFAs suppressed the growth of Verrucomicrobia and Akkermansia, thereby downregulated Amino Acid Metabolism. Additionally, SCFAs could alleviated intestinal inflammation and strengthened intestinal epithelial barrier by inhibiting the TLR4/MyD88/NF-κB pathway. This study demonstrated that PP prevented UC by targeting the immune-microbiota-metabolism axis. As a natural polysaccharide, PP could serve as a promising dietary intervention for UC.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Ulcerative Colitis
Dysbiosis of the Gut Microbiota
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...